View
0
Download
0
Category
Preview:
Citation preview
Confidential and Proprietary
Moving Precision Health from Rhetoric to Reality
August, 2019
Safe Harbor statement
This presentation contains forward-looking statements. These statements relate to future events or SomaLogic’s future financial performance. Any statements that are not statements of historical fact should be considered forward-looking statements. There are a number of important factors that could cause SomaLogic’s actual results to differ materially from the assumptions made in the model, including changes in market conditions, inability to penetrate markets, changes in technology, and changes in pricing models. SomaLogic disclaims any obligation to update any forward-looking statement.
2
Experienced leadership
Roy SmytheChief Executive Officer
Melody HarrisPresident
Matt NorkunasChief Financial Officer
Nebojsa JanjicChief Science Officer
Stephen WilliamsChief Medical Officer
Alan WilliamsChief Development and Operations
Fintan SteeleChief Communications and Culture
About SomaLogic
▶ Founded in 2000 by Larry Gold, PhD
▶ Located in Boulder, CO
▶ 200 employees
▶ $600M invested to date ($365M in equity)
Basic facts
Larry Gold, Founder & ChairmanSynergen, NeXagen, NeXstar
Charles M. LillisFormer Chairman and CEO, Media One Group, Inc.; Co-founder and Managing Partner, LoneTree Capital
Jessica MathewsFormer President, Carnegie Endowment forInternational Peace
Alister (Al) W. ReynoldsFormer SVP of US Operations, Quest Diagnostics
Terry L. RandallPresident-CEO, Heritage Capital, LLC
Takayuki ShiratsuchiOperating Officer, General Manager of Basic Research, Otsuka Pharmaceuticals
Roy SmytheCEO, SomaLogic; former Chief Medical Officer for Strategy and Partnerships, Royal Philips
Jun WangFounder and CEO of iCarbonX,former CEO and Chairman of BGI
Board of Directors Advisors
Sir Marc FeldmannEmeritus Professor, University of Oxford, UK
Peter GanzProfessor, UCSF School of Medicine
David LawrenceFormer Chairman & CEO, Kaiser Permanente
Craig MundiePresident, Mundie & Associates; Former Chief Research and Strategy Officer, Microsoft
Russell RayFormer Vice Chair and Managing Director of Healthcare Investment Banking, Stifel
Elio RiboliDirector, School of Public Health, Imperial College, London
John Stuelpnagel Executive Chairman, Ariosa Diagnostics; Chairman, 10x Genomics; Founder and former CEO and COO, Illumina
3
Nature can refuse to speak, but she cannot give a wrong answer.
Charles Brenton Huggins, MDNobel Prize for Medicine or Physiology, 1966
4
The well-known challenge of precision health
THE TOP 5%
WALKING WOUNDED
UNDER THE RADAR
ON THE LEDGE
“HEALTHY”
PREDISPOSED
5
Moving fromrhetoric to reality
▶ To understand human biology in context, you must translate the “language” of proteins in real-time.
▶ After 20 years of effort, SomaLogicleads the world in translating proteins into impactful health information.
▶ We are creating a truly transformational protein-based precision health information company.
6
Commercial launch of SomaSignal™ tests
100
5,000-plex launched under CLIA
Creating a transformational protein-based precision health information company
7
20062000-2005 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Som
aS
can®
ple
x si
ze
Dilu
tive
fun
din
g ($
M)
4005000
1000
SomaLogic founded by Larry Gold
First version of SomaScan®
Assay deployed
First commercial sale of SomaScan® Assay
First collaborative deal with Novartis
Pivot from life sci tools business to clinical proteomics / health information
Roy Smythe (CEO) and Melody Harris (President) join SomaLogic
CLIA / CAP accreditation
Expansion of Novartis agreement
First scientific publication of SomaScan® Assay
yr.
RED – SomaScan plex sizeBLUE – Dilutive funding
Publication in JAMA presages first SomaSignal™ test
SomaLogic Differentiation in the Market
8
What genes measure, what proteins measureWhile beneficial, genomic testing is neither comprehensive nor contextual
9
Precision health relies on the acquisition and interpretation of “real-time” biologic data
10
mRNA
Molecule that carries “directions” for
protein synthesis
Proteins
Primary functional and structural molecules for all
biological processes
DNA
Hereditary material that encodes biological
molecules
One-and-done Repeat regularly
From static to dynamic measurements
New applications of genomics can expand progress, but proteomics offers near limitless growth
11
Protein measurement
Covers all of human biology in real time - all diseases, conditions and
normal processes
(SomaLogic)
Cell-free DNA
Limited to diseases and conditions that shed
marker DNA
(E.g., Guardant)
T-cell recognition
Limited to diseases and conditions that effectively
activate T-cells
(E.g., Adaptive Biotechnologies)
Several direct competitors No direct competitors
The SomaScan® Assay uniquely meets the requirements for proteomics-based precision health
12
Breadth (number)
Depth (low conc)
Speed
Cost
Scalability
Reproducibility
Sample needed
Antibodies Mass spec SomaScan®
- Yes
- No
- Partial
▶ Proprietary technology / science
▶ ~5,000 proteins in each sample(equivalent to 5,000 ELISAs)
▶ Can detect low concentration proteins
▶ Many assays can run simultaneously(faster, less expensive)
▶ Scalable and reproducible
▶ Runs in CLIA-certified laboratory
▶ Small biological sample volume
How we measure proteins - SOMAmer® reagents and the SomaScan® AssayTurning a protein measurement challenge into a DNA measurement solution
Platelet-derived growth factor and specific SOMAmer reagentCustom array measuring ~5K SOMAmer reagents
Slow Off-rate Modified Aptamers (SOMAmers): Next generation protein
binders
Synthetic single-stranded DNA structures, with ”protein-like” modifications
The SomaScan® Assay combines 1,000s of different SOMAmer® reagents to measure
1,000s of different proteins in a small volume of biological sample
Unmatched specificity, sensitivity, dynamic range, reproducibility, scalability and speed
13
The SomaScan® Assay is scalable, and has created the world’s largest clinical proteomics database
* At time of acquisition
GuardantHealth
SomaLogicFoundationMedicine
AdaptiveBiotechnologies
80k 100k
180k*
300k
~300k samples to date on the SomaScan Assay
100k
300k
200k
# sa
mpl
es
14
>200
>600
~300ksamples
processed to date using the
SomaScan Assay
peer-reviewedpublications on the technology and its
applications
patents issued and pending worldwide
World-class strategic partnerships
> 100 academic collaborations
▶ Massachusetts General Hospital▶ Dana Farber Cancer Institute▶ Beth Israel Deaconess Medical Center▶ Johns Hopkins University▶ Yale University▶ University of Pennsylvania▶ University of California, San Francisco▶ Erasmus Medical Center▶ Oxford University▶ University of Cambridge
The SomaScan® Assay has been heavily vetted by collaborators, publications and patents
15
Our product development process - from proteins to health information
1
2
3
4
5
6
7
8
9
10
11
12
19
13
14
15
16
17
18
20
21
~300ksamples
processed to date using the
SomaScan Assay SomaSignal™ tests
16
SomaSignal™ tests undergo rigorous developmentExample: Cardiovascular Secondary Event Prediction
▶ Predefined minimum performance criteria• A positive Net Reclassification Index (NRI) compared with
best combination of risk factors▶ Model output:
• 4 year relative probability of any major CV event or death
▶ Actual performance• Model has 27 proteins and no demographic factors• The NRI vs. risk factors was highly positive (+0.53 in
validation)• The AUC (0.74 in validation) was superior to risk factors
(0.53)
17
HUNT 3 (Norway) N = 606
ARIC (USA) N = 784
Training Set (no known disease)
Independent Replication Set
Machine learning approaches are employed, and models vary between tens and hundreds of informative proteins
SomaSignal™ tests versus existing diagnostic alternatives, and polygenic risk assessment
CV Primary vs. outcomes
CV Secondary vs. outcomes
Liver fat vs. ultrasound
% Body Fat vs. DEXA
Lean body mass vs. DEXA
Cardio-respiratory fitness vs. VO2 max
Alcohol impact vs. self report
Visceral fat vs. DEXA
Glucose tolerance vs. OGTT
Performance (r2 [0-1.0] or AUC [0.5-1.0])
Best possible performance
ACC risk
Best factors
Impedance
Best factors
Impedance
Best factors
Adiponectin
Liver enzyme
Best factors
18
We leverage a network effect to develop new SomaSignal tests, and make them increasingly informative
BiobanksPharmaAcademicsClinical Partners
Data repositoryIT / analytics
101010001101101010001011100100100001000011111110
Clinical andconsumer
1
2
3
4
5
6
7
8
9
10
11
12
19
13
14
15
16
17
18
20
21
19
SomaSignal™ tests
By 2024, there will be more than 1 million human specimens in the SomaLogicclinical proteomics database, and by 2028 - more than 4 million
One tube of blood – unlimited tests, unlimited timesThe SomaScan® Platform scales like a digital platform
Value = X (one tube) Value + Xn (many tests) Value + Xn(X) (many times)
Sept Oct Nov
Dec Jan Feb
How am I doing now?Making progress?
How is my patient doing now?Making progress?
SomaSignal™ tests
20
There are more than 100 tests in the SomaSignal™ pipeline – and all can be run on any one sample
21
Medical
Primary CV riskSecondary CV riskLiver fatGlucose tolerance
Health/Wellness
Resting metabolic rateMacronutrient statusAerobic Fitness/VO2 MaxAlcohol consumptionVisceral Body FatLean Body MassPercent Body Fat
Medical
NASHNASH subtypesCancer susceptibilityChronic Kidney Disease prognosisCongestive Heart Failure prognosisCongestive Heart Failure type
Functionally relevant CHDStatin adherencePredict Renal Failure w/ CVDeGFR (kidney function)Predict Type II Diabetes onsetPredict Diabetic Retinopathy
Health/Wellness
HealthspanSleep qualityAlzheimers/Dementia riskCognitive functionBiologic/functional ageTraining statusSocial deprivationSmoking status
Physical activityBody weightBone Mineral MassLifespanEnergy balanceVitamin C levelInsulin sensitivity
Medical
Cancer risk (top 15)Cancer risk (other subtypes)Acute Kidney InjuryCKD w/diabetesCOPD risk/risk of progressionAnticoagulant adherenceCHF hospitalization riskCHF therapy sensitivity
CV disease w/ diabetesCoronary artery calcium surrogatePrimary CV risk (multiple subtypes)eGFR (kidney function) trajectoryFunctional status/ability w/agingPulmonary functionSleep apnea riskPeripheral vascular function
Health/Wellness
Circadian cycleDaily physical activityMetabolic flexibilityReproductive healthCognitive trajectoryDepression/mood w/agingFrailtyGenderGrip strength w/agingMaximum strength
Mental stressInflammatory loadMicrobiome diversityDiet change/hypertension correlationTraining program recommendationEnduranceFood allergy riskJoint healthMacronutrient status/weight loss correlation
Fall 2019 Release 2019 - 2020 2020+
SomaLogic Business Plan and Direction
22
Go-To-Market Plan:Support for precision health across channels
23
Self Pay and Concierge
Medical
Retail/Direct to
Consumer
Health assessments and care delivery
SomaScan® Assay protein quantification and SomaSignal™ tests for clinical drug trials
Data collaboration for SomaLogic proteomics database development
Patient / Individual
Risk-bearing Medical (health
systems, etc.)
2019 2020 2021Pharma,
Biotech and Academic
2017
The go-to-market sequence rationale is sound
24
Retail/Direct to
Consumer
Pharma, Biotech and Academic
Self-Pay and Concierge
Medical
Risk-bearing Medical (health
systems, etc.)
Development of SomaLogic proteomics
database
Source of recurring baseline development
revenue
Develop health system utility proof
Self-pay experience in hand
Larger platform of medical tests for pop health management
Motivated providers and patients
Dispensable income
KOL development for risk bearing medical
and DTC
Medical acceptance and advocacy
Consumer launch
Develop DTC commercial
competencies
Lowered assay for DTC price points
Urine as a matrix
25
Retail/Direct to
Consumer
Pharma, Biotech and Academic
Self-Pay and Concierge
Medical
Risk-bearing Medical (Health
Systems, etc.)
Compete in global market
Clinical trial support –patient selection
Clinical trial support –drug discovery
Disease understanding
Enhanced experience
Compete in innovative market
Efficient referrals
MD productivity
Lower cost diagnostics
Cost-effective baseline
Enhanced experience
Population mgmt
Decrease hospitalizations
MD productivity
Lower cost diagnostics
Cost-effective baseline
Financial / family planning
Disease self-mgmt
Healthier lifestyle opportunity
Convenience
The value proposition for each market is substantial
The US market opportunity alone is $50B
▶ Two-year continuous engagement with external firm for:• Market research and interviews for product concept and development• Validation of product concept, go-to-market plan and value proposition• Sizing and characterization of markets
• Sensitivity analyses for pricing and revenues
26
Retail/Direct to
Consumer
Pharma, Biotech and Academic
Self-Pay and Concierge
Medical
Risk-bearing Medical (health
systems, etc.)
$900M-$2B $3.7B $13.7B $30.4BTAM (US):
Data aggregation and advanced computing will create significant revenue opportunities4M human specimens in the SomaLogic database by 2028
▶ Consumer Decision Support Engines• ”With your proteomic profile, you should do X to improve sleep, fitness,
etc.”
▶ Clinical Decision Support Engines• “With this proteomic profile, this patient will benefit from treatment X”
▶ “Predicting the Next Proteome”• Analytics allowing the use of intercurrent urine as matrix, or no biologic
specimen at all to register proteomic profile and prediction(s)
▶ The Liquid Physical Exam• Mapping of typical history, physical and conventional diagnostic test data
points to proteomic data, at times eliminating their need
▶ Monetization of Comprehensive Database Insights
27
▶ To understand human biology in context, you must translate the “language” of proteins in real-time, and ideally repeatedly over time.
▶ After 20 years of effort, SomaLogicleads the world in translating proteins into impactful health information, and the value of our information will compound greatly over time.
▶ We are creating a truly transformational protein-based precision health information company.
28
Recommended